Related Experiment Videos
Medication and parent training in children with pervasive developmental disorders and serious behavior problems:
Michael G Aman1, Christopher J McDougle, Lawrence Scahill
1The Nisonger Center UCEDD, Ohio State University, Columbus, OH 43210-1257, USA. aman.1@osu.edu
Insights
Combined treatment with risperidone and parent training (PT) significantly improved behavioral problems in children with pervasive developmental disorders (PDDs). This approach was more effective than medication alone (MED) and used a lower risperidone dose.
Area of Science:
- Child Psychiatry
- Neurodevelopmental Disorders
- Behavioral Therapy
Background:
- Children with pervasive developmental disorders (PDDs) often exhibit severe behavioral problems.
- These behaviors can significantly impair daily functioning.
Purpose of the Study:
- To evaluate if combined treatment (COMB) with risperidone and parent training (PT) is superior to medication alone (MED) for severe behavioral issues in children with PDDs.
Main Methods:
- A 24-week, randomized clinical trial involving 124 children (ages 4-13) with PDDs and severe behaviors.
- Participants were assigned to COMB (risperidone + PT) or MED (risperidone).
- The Home Situations Questionnaire (HSQ) was the primary outcome measure.
Main Results:
- COMB demonstrated superior improvement in behavioral problems compared to MED, as measured by the HSQ (p = .006).
- Significant reductions were observed in irritability, stereotypic behavior, and hyperactivity/noncompliance with COMB.
- The COMB group required a lower mean risperidone dose.
Conclusions:
- Combining medication with parent training is more effective for reducing maladaptive behaviors in children with PDDs than medication alone.
- This combined approach may allow for a reduced dosage of risperidone.
Objective:
Many children with pervasive developmental disorders (PDDs) have serious, functionally impairing behavioral problems. We tested whether combined treatment (COMB) with risperidone and parent training (PT) in behavior management is superior to medication alone (MED) in improving severe behavioral problems in children with PDDs.
Method:
This 24-week, three-site, randomized, parallel-groups clinical trial enrolled 124 children, aged 4 through 13 years, with PDDs, accompanied by frequent tantrums, self-injury, and aggression. The children were randomized 3:2 to COMB (n = 75) or MED (n = 49). The participants received risperidone monotherapy from 0.5 to 3.5 mg/day (with switch to aripiprazole if risperidone was ineffective). Parents in the COMB group (n = 75; 60.5%) received a mean of 10.9 PT sessions. The primary measure of compliance was the Home Situations Questionnaire (HSQ) score.
Results:
Primary: intent-to-treat random effects regression showed that COMB was superior to MED on HSQ (p = .006) [effect size at week 24 (d) = 0.34]. The HSQ score declined from 4.31 (± 1.67) to 1.23 (± 1.36) for COMB compared with 4.16 (± 1.47) to 1.68 (± 1.36) for MED. Secondary: groups did not differ on Clinical Global Impressions-Improvement scores at endpoint; compared with MED, COMB showed significant reductions on Aberrant Behavior Checklist Irritability (d = 0.48; p = .01), Stereotypic Behavior (d = 0.23; p = .04), and Hyperactivity/Noncompliance subscales (d = 0.55; p = .04). Final risperidone mean dose for MED was 2.26 mg/day (0.071 mg/kg), compared with 1.98 mg/day for COMB (0.066 mg/kg) (p = .04).
Conclusions:
Medication plus PT resulted in greater reduction of serious maladaptive behavior than MED in children with PDDs, with a lower risperidone dose.
Related Concept Videos
Operant Conditioning Intervention
In operant conditioning, behaviors that are...
Behavior Modification
A real-world application of operant conditioning principles is applied...
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Drug Therapy
Antianxiety Medications
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...